Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 3:57 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 6,229 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 1 Clear all

Conditions: Renal Cell Carcinoma
Interventions: TRC105 and Axitinib, Axitinib; Drug
Lead sponsor: Tracon Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 28
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Duarte, California + 23 more

Conditions: Epilepsy, Dravet Syndrome
Interventions: GWP42003-P 5 mg/kg/day Dose, Placebo control, GWP42003-P 10 mg/kg/day Dose, GWP42003-P 20 mg/kg/day Dose; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 4 Years to 10 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 8
States / cities: Miami, Florida • Atlanta, Georgia • Chicago, Illinois + 5 more

Conditions: Overweight, Obesity
Interventions: UBT251, Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Cypress, California • Overland Park, Kansas

Conditions: Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasm Metastasis
Interventions: Sofetabart Mipitecan, Paclitaxel, Topotecan, Gemcitabine, Pegylated liposomal doxorubicin (PLD), MIRV, Bevacizumab, Carboplatin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,630 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 85
States / cities: Birmingham, Alabama • Phoenix, Arizona • Burbank, California + 67 more

Conditions: Sleep Disturbance, Sleep Disorder
Interventions: mHealth Stepped-care Intervention, Educational Control Condition, Questionnaire, Interview, Qualitative Interviews, Virtual Reality; Other
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Chronic Rhinitis
Interventions: RhinAer Stylus, Sham; Device
Lead sponsor: Aerin Medical; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 116 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 13
States / cities: Roseville, California • Torrance, California • Plantation, Florida + 10 more

Conditions: Infections, Bacterial
Interventions: GSK2140944 capsule, GSK2140944 tablet, Itraconazole capsule; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Ovarian Cancer
Interventions: Serial Transvaginal Ultrasonography; Procedure
Lead sponsor: John R van Nagell; Other
Eligibility: 24 Years and older · Female only
Enrollment: 65,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1988 – 2026
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Hematologic Malignancies, Acute Leukemia, Myelodysplastic Syndromes (MDS) Other Than RA or RARS Subtypes, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Myeloma, Chronic Myelogenous (or Myeloid) Leukemia (CML) Resistant to STI Therapy
Interventions: Fludarabine, Thiotepa, Total Body Irradiation (TBI), Donor Lymphocyte Infusion (DLI), Melphalan, Hematopoietic stem cell transplantation (HSCT); Drug · Radiation · Biological + 1 more
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Insomnia, Insomnia Chronic, Survivorship
Interventions: The Sleep Treatment Education Program Together (STEP-Together), Coaching Session; Behavioral
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years to 89 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Respiratory Syncytial Virus Infections, Virus Diseases
Interventions: JNJ-53718678, Placebo; Drug
Lead sponsor: Janssen Sciences Ireland UC; Industry
Eligibility: 1 Month to 24 Months
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Kirksville, Missouri

Conditions: Small Cell Lung Cancer
Interventions: Gocatamig, Ifinatamab Deruxtecan (I-DXd), Durvalumab; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 327 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 9
States / cities: Aurora, Colorado • Miami, Florida • Chicago, Illinois + 6 more

Conditions: Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers
Interventions: Anvumetostat, Gemcitabine, Nab-paclitaxel, Modified FOLFIRINOX, RMC-6236; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 29
States / cities: Bakersfield, California • Duarte, California • La Jolla, California + 24 more

Conditions: Kidney Transplant
Interventions: Alemtuzumab; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: CD20 Positive Non Hodgkin Lymphoma
Interventions: CPO107; Drug
Lead sponsor: Conjupro Biotherapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Pompe Disease
Interventions: VAL-1221, RhGAA; Drug
Lead sponsor: Valerion Therapeutics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: Orange, California • Durham, North Carolina

Conditions: Fibrodysplasia Ossificans Progressiva (FOP)
Interventions: Non-Interventional; Other
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: Not listed
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Tarrytown, New York

Conditions: Obese With Comorbidities, Overweight With Comorbidities, Type2 Diabetes
Interventions: HM15136, Placebo; Drug
Lead sponsor: Hanmi Pharmaceutical Company Limited; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: San Diego, California

Conditions: Immune Tolerance
Interventions: Hematopoietic cell transplantation, Total Lymphoid irradiation; Biological · Radiation
Lead sponsor: Stephan Busque; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Congenital Diaphragmatic Hernia
Interventions: Congenital diaphragmatic hernia resuscitation with an intact umbilical cord; Procedure
Lead sponsor: University of Colorado, Denver; Other
Eligibility: Up to 5 Minutes
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Multiple Myeloma, Fatigue
Interventions: AYO light glasses (Experimental), AYO light glasses (Comparator); Device
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 194 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2022
U.S. locations: 3
States / cities: Hackensack, New Jersey • New York, New York

Conditions: Advanced Malignancy, Advanced Solid Tumors, Cancer, Oncology, Oncology Patients, Tumors
Interventions: AMG 820; Drug
Lead sponsor: AmMax Bio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 3
States / cities: Philadelphia, Pennsylvania • Greenville, South Carolina • San Antonio, Texas

Conditions: Diabetes Mellitus, Type 2
Interventions: Family-DSMES, Standard-DSMES; Behavioral
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older
Enrollment: 1,100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Fayetteville, Arkansas

Conditions: Diabetic Retinopathy
Interventions: BI 765128, Sham comparator; Drug · Other
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 11
States / cities: Bakersfield, California • Sacramento, California • Walnut Creek, California + 7 more

Search by objective public record fields.

Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma

A Dose-ranging Pharmacokinetics and Safety Study of GWP42003-P in Children With Dravet Syndrome (GWPCARE1)

A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

Improving Sleep in BMT Survivors

RhinAer Procedure for Treatment of Chronic Rhinitis Study

Relative Bioavailability, Safety, Tolerability, Pharmacokinetics (PK) and Food Effect Study of GSK2140944 in Healthy Subjects

Transvaginal Ultrasonography as a Screening Method for Ovarian Cancer

Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps

Sleep Treatment Education Program for Cancer Survivors: STEP-Together

A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Multiple Doses of Orally Administered JNJ-53718678 in Infants Hospitalized With Respiratory Syncytial Virus (RSV) Infection

A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)

A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)

Immunophenotyping of Peripheral T Cells After T Cell Depletion With Alemtuzumab

Dose Escalation and Expansion Study of CPO107 for Patients With Advanced CD20-positive Non-Hodgkins Lymphoma

VAL-1221 Delivered Intravenously in Ambulatory and Ventilator-free Participants With Late-Onset Pompe Disease

A Non-Interventional Study of Clinical Characteristics and Mortality of US Patients With Fibrodysplasia Ossificans Progressiva (FOP)

Study for Multiple Doses of HM15136(Efpegerglucagon) in Obese or Overweight Subjects With Comorbidities

Delayed Blood Stem Transplantation in HLA Matched Kidney Transplant Recipients to Eliminate Immunosuppressive Drugs.

Resuscitation of Infants With Congenital Diaphragmatic Hernia With an Intact Umbilical Cord

Treating Cancer-Related Fatigue Through Systematic Light Exposure (Light for Fatigue Study)

A Study of AMG 820 in Subjects With Advanced Solid Tumors

Comparative Effectiveness of Family DSMES and Standard DSMES Among Diverse Populations

A Study of BI 765128 in Patients With an Eye Condition Called Diabetic Macular Ischemia Who Have Received Laser Treatment